Linical Co., Ltd. Logo

Linical Co., Ltd.

A global CRO providing a full spectrum of drug development services for biopharma.

2183 | T

Overview

Corporate Details

ISIN(s):
JP3974530002
LEI:
Country:
Japan
Address:
大阪市淀川区宮原1丁目6番1号

Description

Linical is a global Contract Research Organization (CRO) providing a full spectrum of drug development services to biopharmaceutical companies. The company supports clinical trials from early-stage research to large-scale, multinational studies (Phase I-IV). Its services include clinical trial strategy, consulting, monitoring, and quality control. Linical focuses on a collaborative approach to guide clients through the clinical development process, aiming to expedite timelines and achieve enrollment goals without compromising quality.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2022-02-14 08:12
四半期報告書-第17期第3四半期(令和3年10月1日-令和3年12月31日)
Japanese ZIP 172.7 KB
2021-11-15 08:41
四半期報告書-第17期第2四半期(令和3年7月1日-令和3年9月30日)
Japanese ZIP 201.1 KB
2021-08-13 07:49
四半期報告書-第17期第1四半期(令和3年4月1日-令和3年6月30日)
Japanese ZIP 162.3 KB
2021-06-25 09:53
内部統制報告書-第16期(令和2年4月1日-令和3年3月31日)
Japanese ZIP 21.9 KB
2021-06-25 09:52
有価証券報告書-第16期(令和2年4月1日-令和3年3月31日)
Japanese ZIP 1.4 MB
2021-06-25 09:52
確認書
Japanese ZIP 8.1 KB
2021-02-12 08:12
四半期報告書-第16期第3四半期(令和2年10月1日-令和2年12月31日)
Japanese ZIP 159.4 KB
2020-11-13 08:21
四半期報告書-第16期第2四半期(令和2年7月1日-令和2年9月30日)
Japanese ZIP 188.8 KB
2020-08-14 09:13
四半期報告書-第16期第1四半期(令和2年4月1日-令和2年6月30日)
Japanese ZIP 154.2 KB
2020-06-26 08:09
有価証券報告書-第15期(平成31年4月1日-令和2年3月31日)
Japanese ZIP 1.4 MB
2020-02-14 08:37
四半期報告書-第15期第3四半期(令和1年10月1日-令和1年12月31日)
Japanese ZIP 161.9 KB
2019-11-14 08:09
四半期報告書-第15期第2四半期(2019/07/01-2019/09/30)
Japanese ZIP 196.7 KB
2019-08-14 09:09
四半期報告書-第15期第1四半期(2019/04/01-2019/06/30)
Japanese ZIP 151.0 KB
2019-06-26 06:34
有価証券報告書-第14期(平成30年4月1日-平成31年3月31日)
Japanese ZIP 1.4 MB
2019-02-14 08:51
四半期報告書-第14期第3四半期(2018/10/01-2018/12/31)
Japanese ZIP 151.1 KB

Automate Your Workflow. Get a real-time feed of all Linical Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Linical Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Linical Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.